A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma

Journal:
Blood
Published:
Affiliations:
23
Authors:
24
Institutions Authors Share
Washington University in St. Louis (WUSTL), United States of America (USA)
3.000000
0.13
Rutgers Cancer Institute of New Jersey (CINJ), United States of America (USA)
2.000000
0.08
NYU Langone Health, United States of America (USA)
1.000000
0.04
ECOG-ACRIN Cancer Research Group, United States of America (USA)
1.000000
0.04
Dana-Farber Cancer Institute (DFCI), United States of America (USA)
1.000000
0.04
Mayo Clinic, United States of America (USA)
1.000000
0.04
UVA Comprehensive Cancer Center, United States of America (USA)
1.000000
0.04
BC Cancer Agency (BCCA), PHSA, Canada
1.000000
0.04
The University of British Columbia (UBC), Canada
1.000000
0.04
Stanford University School of Medicine, United States of America (USA)
1.000000
0.04
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA)
1.000000
0.04
Stanford Cancer Center, United States of America (USA)
1.000000
0.04
Melvin and Bren Simon Comprehensive Cancer Center, United States of America (USA)
1.000000
0.04
Kaiser Permanente Vallejo Medical Center, United States of America (USA)
1.000000
0.04
The Winship Cancer Institute of Emory University, United States of America (USA)
1.000000
0.04
OU Health Sciences Center (OUHSC), United States of America (USA)
1.000000
0.04
The University of Alabama at Birmingham (UAB), United States of America (USA)
1.000000
0.04
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)
1.000000
0.04
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
1.000000
0.04
Brown University, United States of America (USA)
1.000000
0.04
Roswell Park Cancer Institute (RPCI), United States of America (USA)
0.500000
0.02
University at Buffalo, The State University of New York (SUNY UB), United States of America (USA)
0.500000
0.02